IFC Funds Neolpharma Expansion to Bolster Mexico’s Drug Supply

Mexico imports over 85 percent of its active pharmaceutical ingredients, leaving the national healthcare system dangerously exposed to global supply chain volatility. To counter this, the International Finance Corporation is backing Neolpharma in an expansion project designed to localize production and create 600 skilled manufacturing positions.

Editorial·August 14, 2026·reads: 1,763

IFC Funds Neolpharma Expansion to Bolster Mexico’s Drug Supply

The financing package supports two primary goals: the modernization of an API facility in Cuernavaca and the construction of a new plant dedicated to injectable medicines. By shifting production closer to home, the initiative aims to stabilize the availability of essential medical supplies while reducing reliance on overseas vendors.

Beyond production capacity, the loan introduces a pioneering disability inclusion incentive. Neolpharma will receive a reduction on its loan spread if it meets specific benchmarks for hiring and hosting interns with disabilities. This integration of social equity into corporate financing marks a strategic shift for the IFC, pairing industrial growth with measurable workforce diversification.

Environmental sustainability also sits at the core of the project. The new injectable medicines facility is slated to pursue EDGE Advanced certification, a green-building standard focused on energy and water efficiency. CEO Astrea Ocampo noted that the investment underscores a commitment to innovation and affordability within the Mexican pharmaceutical sector. The move aligns with the World Bank Group’s broader mandate to improve healthcare access for 1.5 billion people globally by 2030, reinforcing national industrial resilience through domestic manufacturing.